Madrigal Pharmaceuticals (MDGL) Other financing activities (2018 - 2026)
Madrigal Pharmaceuticals' (MDGL) quarterly Other financing activities came in at $2.3 million in Q1 2026, down 73.04% year-on-year from $8.6 million in Q1 2025, and down 73.04% on a QoQ basis from $8.6 million in Q1 2025.
Madrigal Pharmaceuticals (MDGL) Other financing activities (2018 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 4 years of Other financing activities data on file, last reported at $2.3 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Madrigal Pharmaceuticals | 15.77 Bn | 15.54 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.33 Mn |
| Mar 31, 2026 | 2.33 Mn |
| Mar 31, 2025 | 8.64 Mn |
| Mar 31, 2025 | 8.64 Mn |
| Sep 30, 2021 | 7,000.00 |
| Sep 30, 2021 | 7,000.00 |
| Sep 30, 2018 | 451,000.00 |
| Sep 30, 2018 | 451,000.00 |